Related Experiment Videos

Cytopathic effect of in situ gene therapy in prostate cancer

G Ayala1, T M Wheeler, M Shalev

  • 1Department of Pathology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.

Human Pathology
|August 3, 2000
PubMed

Insights

This study explored in situ gene therapy for prostate cancer using the Herpes Simplex Virus-Thymidine Kinase gene (HSV-tk) and ganciclovir. Morphologic analysis revealed tumor necrosis and an immune response, suggesting therapeutic effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Prostate cancer remains a significant health concern.
  • In situ gene therapy offers a targeted treatment approach.
  • The Herpes Simplex Virus-Thymidine Kinase (HSV-tk) gene therapy with ganciclovir is being investigated for prostate cancer.

Purpose of the Study:

  • To investigate the morphologic effects of in situ HSV-tk/ganciclovir gene therapy on prostate cancer.
  • To assess the relationship between gene therapy effects, tumor characteristics, and immune response.

Main Methods:

  • Morphologic examination of prostatectomy specimens from patients treated with in situ gene therapy.
  • Volumetric analysis to quantify treatment effects.
  • Immunohistochemical staining to identify inflammatory cell populations (CD20, CD8, macrophages).

Main Results:

  • Observed varying degrees of tumor necrosis and cytopathic changes across Gleason grades.
  • Found that only portions of the tumor exhibited morphologic effects, with an inverse relationship to tumor size.
  • Detected a localized inflammatory response with distinct immune cell profiles in tumor and normal prostate tissues.

Conclusions:

  • The observed morphologic changes are consistent with the cytopathic effects of HSV-tk/ganciclovir gene therapy.
  • The gene therapy appears to trigger a local immune response in prostate cancer patients.
  • Further research is warranted to optimize this in situ gene therapy approach.

Related Concept Videos